Figure 5.

Macrophage immunoreactivity was not altered after a blocker of Src family kinases PP2 treatment in injured spinal cords.

(A) ED-1 immunoreactive cells were not affected in injured spinal cords treated with PP2 compared to PP3 or DMSO-treated spinal cords. Scale bar: 30 μm. Insert shows a high magnification picture (63×) of a microglia at the lesion epicenter in each treatment. Scale bar: 10 μm. (B) PP2 treatment for 28 days did not exert any differences in the amount of infiltrated macrophages in the injured spinal cord, compared to PP3 and DMSO treatment. Densitometric analysis of confocal images demonstrates no significant differences between groups (n = 3). For ED-1 analysis, one-way analysis of variance followed by Bonferroni post hoc test was used to determine the significant differences among samples studied (F_(2,9) = 0.2224, P = 0.8048). Error bars show the standard error of the mean (SEM). PP2: 4-amino-5-(4-chlorophenyl)-7- (t-butyl)pyrazolo[3,4-d]pyramidine; PP3: 4-amino-7-phenylpyrazolo[3,4-d]pyramidine (the inactive analog of PP2); DMSO: dimethyl sulfoxide.